Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $44.34M
• Dividend Yield: N/A
• Average Volume (3M): 502.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: 5489.03%
• EPS Growth: 86.23%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 86,389,100
• 10 Day Avg. Volume: 418,407
• 30 Day Avg. Volume: 502,773
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.27
• Enterprise Value/Revenue: -0.49
• Enterprise Value/Gross Profit: -0.51
• Enterprise Value/Ebitda: 4.33
• 1Y Price Target: $4.50
• Price Target Upside: 782.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $0.50 ▼(-1.96% Downside)

Century Therapeutics' overall stock score is primarily influenced by its financial performance and technical analysis. The company shows strong revenue growth but faces challenges with profitability and cash flow. Technical indicators suggest positive momentum, though caution is warranted due to potential overbought conditions. Valuation metrics reflect typical characteristics of a high-growth biotech firm with ongoing losses.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates successful commercialization efforts and increasing market acceptance of its innovative therapies, supporting long-term business expansion.

Strong Balance Sheet

A strong equity ratio suggests financial stability and lower risk, providing the company with flexibility to invest in R&D and withstand market fluctuations.

Proprietary Technology

The proprietary iPSC technology offers a competitive edge by enabling scalable and customizable cancer treatments, potentially leading to sustained market leadership.

Negative Factors

Operating Losses

Ongoing net losses highlight operational inefficiencies and the challenge of managing high fixed costs, which could hinder profitability and require strategic adjustments.

Negative Cash Flow

Negative cash flow indicates cash burn and reliance on external funding, which may limit the company's ability to invest in growth initiatives and sustain operations long-term.

High Fixed Costs

High fixed costs can pressure margins and profitability, necessitating strategic cost management to improve operational efficiency and financial performance.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of developed therapies. Additionally, the company may receive funding from grants and investments to support its research and development efforts. By focusing on advancing its proprietary iPSC technology, Century aims to establish a strong pipeline of therapies that can be licensed or commercialized, contributing to its overall revenue growth.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics shows significant revenue growth but continues to operate at a net loss with negative EBIT and EBITDA margins. The balance sheet is strong with a high equity ratio and cash reserves, but cash flow is negative, indicating operational inefficiencies.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	114.13M	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	110.93M	6.59M	2.23M	-4.87M	-4.58M	-1.75M
EBITDA	-12.98M	-111.47M	-121.21M	-119.34M	-89.92M	-51.44M
Net Income	-23.28M	-126.57M	-136.67M	-130.93M	-95.82M	-54.66M
Balance Sheet
Total Assets	284.69M	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	155.84M	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	51.48M	53.83M	48.17M	49.41M	23.46M	21.55M
Total Liabilities	74.79M	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	209.90M	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-114.44M	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-114.77M	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	130.27M	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	-209.00K	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 0.51 is above the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.52, and below the 200-day MA of 0.63, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.64 is Neutral, neither overbought nor oversold. The STOCH value of 76.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	55 Neutral	$148.41M	―	-73.39%	―	-27.33%	34.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KRON	51 Neutral	―	―	―	―	21.15%	46.44%
IPSC	48 Neutral	$44.34M	―	-10.78%	―	5489.03%	86.23%
CELU	46 Neutral	$56.85M	―	-6367.24%	―	4.45%	45.19%
PASG	44 Neutral	$24.81M	―	-88.27%	―	―	32.57%
JSPR	35 Underperform	$69.53M	―	-146.87%	―	―	-17.96%

Century Therapeutics Corporate Events

Century Therapeutics Granted Nasdaq Compliance Extension

On February 26, 2025, Century Therapeutics received a deficiency letter from Nasdaq due to non-compliance with the $1.00 minimum bid price requirement. Despite failing to meet the initial compliance deadline of August 26, 2025, Nasdaq granted an extension until February 23, 2026, and approved the company’s transfer to The Nasdaq Capital Market. Century Therapeutics plans to monitor its stock price and consider a reverse stock split to regain compliance, although there is no assurance of success.

Century Therapeutics Reports Q2 Results and Leadership Change

On August 14, 2025, Century Therapeutics announced its second quarter financial results and business updates, highlighting ongoing patient dosing in the CALiPSO-1 trial and progress in IND-enabling studies for CNTY-308. The company extended its cash runway into the fourth quarter of 2027 following a workforce reduction and strategic focus on high-potential programs. CEO Brent Pfeiffenberger was appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor. The company remains on track to report clinical data for CNTY-101 by the end of 2025 and plans to initiate clinical studies for CNTY-308 in 2026.

Century Therapeutics Announces Major Workforce Reduction

On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.

Century Therapeutics Holds 2025 Annual Stockholders Meeting

On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.